Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
The effects of intravitreal adalimumab injection on pseudophakic macular edema
View through CrossRef
Abstract
Objective
Pseudophakic macular edema is a frequent complication following cataract surgery. Inflammation is a major etiologic factor in the development of pseudophakic cystoid macular edema. Tumor necrosis factor-alpha has an important role in ocular inflammation. Adalimumab (Humira) is an inhibitor of tumor necrosis factor-alpha that has been approved in the United States. An open-label, uncontrolled, prospective, interventional study of five consecutive patients (5 eyes) with cystoid macular edema who were treated with off-label intravitreal adalimumab at Khalili Hospital was conducted. Slit-lamp examination and optical coherence tomography were done for all patients.
Results
No statistically significant difference was detected between best corrected visual acuity and central macular thickness before and after injection in pseudophakic macular edema. One patient developed uveitis approximately 2 weeks after injection. Based on the results, adalimumab does not appear to be an effective treatment for pseudophakic macular edema, and it may cause uveitis. Caution should be exercised when using this drug.
Trial registration Iranian Registry of Clinical Trials IRCT2016100430130N1, 2016.12.03, Retrospectively registered
Springer Science and Business Media LLC
Title: The effects of intravitreal adalimumab injection on pseudophakic macular edema
Description:
Abstract
Objective
Pseudophakic macular edema is a frequent complication following cataract surgery.
Inflammation is a major etiologic factor in the development of pseudophakic cystoid macular edema.
Tumor necrosis factor-alpha has an important role in ocular inflammation.
Adalimumab (Humira) is an inhibitor of tumor necrosis factor-alpha that has been approved in the United States.
An open-label, uncontrolled, prospective, interventional study of five consecutive patients (5 eyes) with cystoid macular edema who were treated with off-label intravitreal adalimumab at Khalili Hospital was conducted.
Slit-lamp examination and optical coherence tomography were done for all patients.
Results
No statistically significant difference was detected between best corrected visual acuity and central macular thickness before and after injection in pseudophakic macular edema.
One patient developed uveitis approximately 2 weeks after injection.
Based on the results, adalimumab does not appear to be an effective treatment for pseudophakic macular edema, and it may cause uveitis.
Caution should be exercised when using this drug.
Trial registration Iranian Registry of Clinical Trials IRCT2016100430130N1, 2016.
12.
03, Retrospectively registered.
Related Results
The effect of intravitreal injections for diabetic macular edema on intraocular pressure: Comparative study
The effect of intravitreal injections for diabetic macular edema on intraocular pressure: Comparative study
Abstract
Objective: The study's goal is to determine how IOP gets affected following intravitreal injection of various anti-VEGF for diabetic macular edema (DME) over 2 mon...
Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis
Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis
Background: Adalimumab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult rheumatoid arthritis (RA), and subsequently approved for pediatri...
Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy
Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy
Summary
Background
Adalimumab is approved for use in patients with moderate to severe Crohn's dise...
Clinical Outcomes of Descemet Membrane Endothelial Keratoplasty in Pseudophakic Eyes Compared With Triple-DMEK at 1-Year Follow-up
Clinical Outcomes of Descemet Membrane Endothelial Keratoplasty in Pseudophakic Eyes Compared With Triple-DMEK at 1-Year Follow-up
Purpose:
To compare the survival rate 1 year after Descemet membrane endothelial keratoplasty (DMEK) in pseudophakic eyes versus combined phacoemulsification and DMEK (...
Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment
Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment
Background/Objectives: Dose escalation has been commonly used to achieve and maintain response. We aimed to compare the outcomes of adalimumab or infliximab dose escalation in infl...
Early model-based precision-dosing at home to guide adalimumab therapy
Early model-based precision-dosing at home to guide adalimumab therapy
1. Aims Underdosing of adalimumab can result in non-response and poor
disease control. In this study we investigated the prediction of
adalimumab levels with population pharmacokin...
Intravitreal ranibizumab and bevacizumab to treat diabetic macular edema
Intravitreal ranibizumab and bevacizumab to treat diabetic macular edema
Abstract Purpose To report the comparative efficacy of intravitreal bevacizumab and ranibizumab in the treatment of diabetic macular oedema (DME). Methods Interventional, case repo...
DEXAMETHASONE IMPLANT VERSUS TOPICAL CARBONIC ANHYDRASE INHIBITORS IN PATIENTS WITH BILATERAL RETINITIS PIGMENTOSA–RELATED CYSTOID MACULAR EDEMA
DEXAMETHASONE IMPLANT VERSUS TOPICAL CARBONIC ANHYDRASE INHIBITORS IN PATIENTS WITH BILATERAL RETINITIS PIGMENTOSA–RELATED CYSTOID MACULAR EDEMA
Purpose:
To compare within-subject efficacy and safety of intravitreal dexamethasone implant and topical carbonic anhydrase inhibitors in the treatment of retinitis pig...